Initial Treatment for Anaplastic Large Cell Lymphoma

Treatment Approach

Dose reductions due to hematological toxicity should be avoided to maintain treatment efficacy, as recommended by the European Society for Medical Oncology 1, 2
Prophylactic use of hematopoietic growth factors is justified in cases of febrile neutropenia, according to the European Society for Medical Oncology 1, 2

For patients with high tumor burden, a prephase treatment with corticosteroids may help prevent tumor lysis syndrome, as suggested by medical insights 3
CNS prophylaxis should be considered in high-risk patients with more than two adverse parameters according to the International Prognostic Index (IPI), especially with involvement of bone marrow, testis, spine, or base of the skull, as recommended by the European Society for Medical Oncology 1, 2
Response evaluation should be performed after 2-4 cycles and after completion of treatment using appropriate radiological tests, according to the European Society for Medical Oncology 1, 2

Follow-up should include history and physical examination every 3 months for 2 years, every 6 months for 3 more years, and then once a year, as recommended by the European Society for Medical Oncology 1, 2
Blood count and a similar blood test should be monitored at 3, 6, 12, and 24 months, according to the European Society for Medical Oncology 1, 2
Radiological examinations should be performed at 6, 12, and 24 months after end of treatment, as recommended by the European Society for Medical Oncology 1, 2
Patients who received neck irradiation should have thyroid function monitored at 1, 2, and at least at 5 years, according to the European Society for Medical Oncology 1, 2